Lupin's Aurangabad facility clears U.S. FDA inspection

Lupin Limited, a global pharmaceutical major, announced its Chhatrapati Sambhajinagar (Aurangabad) facility has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA). This positive outcome follows a product-specific Pre-Approval Inspection conducted from September 1 to September 5, 2025.

Nilesh Gupta, managing director of Lupin, emphasized that this report underscores the company's commitment to maintaining the highest standards of quality and compliance. The favorable EIR is expected to bolster Lupin's position in delivering trusted healthcare solutions to patients globally.

Lupin, headquartered in Mumbai, India, has operations spanning over 100 markets. The company specializes in various pharmaceutical products, including branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. It maintains 15 manufacturing sites and 7 research centers worldwide.